ArticleChinese medical journal2026
Clonal hematopoiesis is associated with future diseases and mortality.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClonal hematopoiesis is a proposed marker of aging. Clonal hematopoiesis of indeterminate potential (CHIP) is a candidate risk factor for atherosclerotic cardiovascular diseases, hematological malignancies, and all-cause mortality, while its associations with the diseases of other systems and cause-specific mortality remain inconclusive.
methodsWe estimated the longitudinal risk for CHIP with 70 common diseases, all-cause, and cause-specific mortality among 431,546 participants in the UK Biobank. Two-sample Mendelian randomization analyses were performed to test the causal associations of CHIP with incident diseases. Cox proportional hazard regression model was used to generate the hazard ratio [HR] and 95% confidence interval [CI] for each CHIP phenotype with the common health-related outcomes. Also evaluated the joint associations between CHIP and telomere length for diseases and mortalities.
resultsThis study included 431,546 participants (mean age, 56.49 years; 45.7% male), of whom 20,274 had CHIP. CHIP at baseline was associated with increased risk of cancers (HR = 1.14, 95% CI 1.10-1.17), infections (HR = 1.12, 95% CI 1.07-1.16), ischemic heart diseases (HR = 1.07, 95% CI 1.02-1.12), diseases of the blood (HR = 1.31, 95% CI 1.26-1.37), nervous (HR = 1.05, 95% CI 1.01-1.10), respiratory (HR = 1.10, 95% CI 1.06-1.13), and genitourinary systems (HR = 1.10, 95% CI 1.07-1.14), and related mortality (false discovery rate <0.05). CHIP carriers were also at elevated risk of incident mental (HR = 1.07, 95% CI 1.03-1.12) and dermatological (HR = 1.07, 95% CI 1.03-1.11) disorders and mortality due to circulatory system (HR = 1.19, 95% CI 1.11-1.28). Most of the associations between CHIP and diseases or mortalities were robust after adjustment for inflammatory parameters. Large clone size CHIP had higher longitudinal risks compared with small clone size or overall CHIP. CHIP due to TET2 mutation was associated with more outcomes than other common CHIP driver genes. Significant interactions were observed between CHIP and short telomere length, the additive and multiplicative effects on the risk of diseases and mortalities were more obvious among large clone size CHIP.
conclusionThis study showed that CHIP was associated with diseases and mortalities of multiple systems, suggesting CHIP was a candidate risk factor for human health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.